Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sierra Oncology Inc (SRRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Sierra Oncology Reports Third Quarter Results

- Chk1 inhibitor SRA737 Monotherapy trial expanded to eight leading centers across the UK -- On track to provide planned SRA737 Program Update in February 2018 - - $107.8 million cash expected to fund...

SRRA : 2.90 (-1.02%)
Sierra Oncology Reports Third Quarter Results

Chk1 inhibitor SRA737 Monotherapy trial expanded to eight leading centers across the UK - - On track to provide planned SRA737 Program Update in February 2018 - - $107.8 million cash expected to fund...

SRRA : 2.90 (-1.02%)
Sierra Oncology to Present at the Jefferies 2017 London Healthcare Conference

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 4:00 p.m. GMT on November 16, 2017 -

SRRA : 2.90 (-1.02%)
Sierra Oncology to Present at the Jefferies 2017 London Healthcare Conference

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 4:00 p.m. GMT on November 16, 2017 -

SRRA : 2.90 (-1.02%)
Sierra Oncology to Present at the Jefferies 2017 London Healthcare Conference

"Beyond PARP - Next Generation DDR Therapeutics" scheduled for 4:00 p.m. GMT on November 16, 2017 -

SRRA : 2.90 (-1.02%)
Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development Strategy

- SRA737 demonstrates synergy with replication stress-inducing agents -- SRA737 plus gemcitabine efficacious in gemcitabine-resistant tumor models -- SRA737 potentiated by novel sub-therapeutic gemcitabine...

SRRA : 2.90 (-1.02%)
Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development Strategy

SRA737 demonstrates synergy with replication stress-inducing agents -- SRA737 plus gemcitabine efficacious in gemcitabine-resistant tumor models -- SRA737 potentiated by novel sub-therapeutic gemcitabine...

SRRA : 2.90 (-1.02%)
Sierra Oncology Appoints Dr. Andrew Allen to its Board of Directors

Dr. Allen, key contributor in the advancement of PARP inhibitors, to support Sierra in developing next-generation DDR therapeutics -

SRRA : 2.90 (-1.02%)
CLVS : 62.90 (+1.21%)
EPZM : 12.85 (-3.02%)
Sierra Oncology Appoints Dr. Andrew Allen to its Board of Directors

- Dr. Allen, key contributor in the advancement of PARP inhibitors, to support Sierra in developing next-generation DDR therapeutics -

SRRA : 2.90 (-1.02%)
CLVS : 62.90 (+1.21%)
EPZM : 12.85 (-3.02%)
Sierra Oncology to Report Chk1 Inhibitor SRA737 Preclinical Data at AACR-NCI-EORTC 2017

Chk1 inhibitor SRA737 demonstrates chemical synthetic lethality with replication stress-inducing agents, including potentiation by novel low-dose gemcitabine combination, in preclinical models of cancer...

SRRA : 2.90 (-1.02%)
Sierra Oncology to Report Chk1 Inhibitor SRA737 Preclinical Data at AACR-NCI-EORTC 2017

- Chk1 inhibitor SRA737 demonstrates chemical synthetic lethality with replication stress-inducing agents, including potentiation by novel low-dose gemcitabine combination, in preclinical models of cancer...

SRRA : 2.90 (-1.02%)
Sierra Oncology to Report Chk1 Inhibitor SRA737 Preclinical Data at AACR-NCI-EORTC 2017

- Chk1 inhibitor SRA737 demonstrates chemical synthetic lethality with replication stress-inducing agents, including potentiation by novel low-dose gemcitabine combination, in preclinical models of cancer...

SRRA : 2.90 (-1.02%)
Sierra Oncology to Present at the 2017 BIO Investor Forum

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 11:00 am PT on October 17, 2017 -

SRRA : 2.90 (-1.02%)
Sierra Oncology to Present at the 2017 BIO Investor Forum

"Beyond PARP - Next Generation DDR Therapeutics" scheduled for 11:00 am PT on October 17, 2017 -

SRRA : 2.90 (-1.02%)
Sierra Oncology to host Key Opinion Leader Meeting "Beyond PARP: The Clinical Potential of Next Generation DNA Damage Response (DDR) Therapeutics" on October 12th in NY

Dr. Leonard Post, Dr. Eric J. Brown, and Dr. Geoffrey I. Shapiro to discuss DDR scientific and clinical development -

SRRA : 2.90 (-1.02%)
Sierra Oncology to host Key Opinion Leader Meeting "Beyond PARP: The Clinical Potential of Next Generation DNA Damage Response (DDR) Therapeutics" on October 12th in NY

- Dr. Leonard Post, Dr. Eric J. Brown, and Dr. Geoffrey I. Shapiro to discuss DDR scientific and clinical development -

SRRA : 2.90 (-1.02%)
Sierra Oncology to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 8:35 am ET on September 26, 2017 -

SRRA : 2.90 (-1.02%)
Sierra Oncology to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 8:35 am ET on September 26, 2017 -

SRRA : 2.90 (-1.02%)
Sierra Oncology to Host KOL Call with Dr. Thomas Helleday presenting "DNA Damage Response (DDR) Targets Beyond PARP"

Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced...

SRRA : 2.90 (-1.02%)
Sierra Oncology to Host KOL Call with Dr. Thomas Helleday presenting "DNA Damage Response (DDR) Targets Beyond PARP"

Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced...

SRRA : 2.90 (-1.02%)

Van Meerten Stock Picks

5 Great Mid Caps
  Today you will find that I have varied a little bit from my usual search criteria.
KBH -0.24 , IPGP +1.39 , FSLR +0.03 , NVR +30.58 , TTWO +1.42
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 +0.09%) this morning are up +0.08% and European stocks are down -0.12% . Most global stocks markets moved higher ahead of central bank meetings this week from the Fed, ECB and BOE. U.S.... Read More

Chart of the Day

Chart of the Day

Red Rocks Resorts (RRR) is the Barchart Chart of the Day.  The gamong company has a Trend Spotter buy signal, a Weoghted Alpha of 57.24+ and gained 37.80% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures ended the Monday session with most contracts 2 to 4 cents lower, pressured by another week of low export inspections. The USDA announced a private export sale of 110,000 MT of corn to Mexico for 17/18 delivery this morning. Their weekly ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.